Research programme: synthetic macrocycles - Ensemble Therapeutics/Bristol-Myers Squibb
Latest Information Update: 09 Jan 2012
At a glance
- Originator Bristol-Myers Squibb; Ensemble Discovery
- Developer Bristol-Myers Squibb; Ensemble Therapeutics
- Class Macrocyclic compounds; Small molecules
- Mechanism of Action Protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Unspecified